Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.39 |
| ▸ | FPR1 | P21462 | 2/20 | 0.38 |
| ▸ | FPR2 | P25090 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6983760 | 0.92 | F10 (0.50) | F10PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4681031 | 0.90 | F10 (0.57) | F10FPR1FPR2 | |
| SCHEMBL6988849 | 0.89 | F10 (0.46) | F10FPR1FPR2 | |
| SCHEMBL4680343 | 0.82 | F10 (0.56) | F10PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4681028 | 0.78 | F10 (0.51) | F10FPR1FPR2 | |
| SCHEMBL4480981 | 0.73 | F10 (0.62) | F10 | |
| SCHEMBL28704468 | 0.73 | FPR2 (0.69) | FPR1FPR2 | |
| SCHEMBL6989555 | 0.71 | F10 (0.43) | F10FPR1FPR2 | |
| SCHEMBL6986900 | 0.70 | PSEN1 (0.51) | F10PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4681207 | 0.69 | F10 (0.67) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337251-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-08-27 | — | — | EP | claimed |
| WO-2002102380-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-12-27 | — | — | WO | claimed |